The high-risk group had at least one positive capsule-sponge biomarker, namely, aberrant p53, equivocal p53, glandular atypia, or atypia of uncertain significance, the moderate-risk group was negative for both capsule-sponge biomarkers but positive for the clinical risk factors (ie, ultralong Barrett's oesophagus segment [M>10 or C>6] or patients with a long segment [M>5 or C3] and either male or age >60 years), and the low-risk group was negative for both capsule-sponge and clinical biomarkers. The high-risk group was further stratified into high risk tier 1 and 2 depending on their biomarker positivity (ie, tier 1 has glandular atypia and aberrant p53; tier 2 is any other combination of biomarker positivity, this includes only equivocal or aberrant p53 staining, only glandular atypia or atypia of uncertain significance, glandular atypia with equivocal p53 staining, and atypia of uncertain significance with aberrant or equivocal p53 staining).
01021-9%2Ffig1_a.webp&w=1920&q=75 "Learn How to Make Workflow for Your Research Paper")